Navigation Links
Thoratec Reports 34 Percent Increase in 2008 Revenues
Date:2/5/2009

graphic and product mix, and unfavorable manufacturing variances.

Operating expenses for 2008 and 2007 on a GAAP basis were $160.3 million and $138.5 million, respectively. On a non-GAAP basis, operating expenses in 2008 were $138.0 million versus $116.1 million a year ago. Operating expenses on a non-GAAP basis are described later in this press release. The year-over- year increase in operating expense is due primarily to product and market development initiatives, commercialization efforts around the HeartMate II and higher compensation expense.

The company's GAAP effective tax rate for 2008 was 26.9 percent versus a tax benefit of 38.1 percent a year ago. The non-GAAP tax rate for the full year, which is described later in this press release, was 32.6 percent versus 29.0 percent in 2007. The principle cause of the rate increase in 2008 was higher income before taxes.

On a GAAP and non-GAAP basis, the company's convertible debt was dilutive to the company's diluted weighted average shares outstanding for the fourth quarter and full year 2008. The company's convertible debt was also dilutive on a non-GAAP basis for the full year 2007. The increase in dilutive shares was approximately 7.3 million shares.

Cash and investments at the end of the quarter were $278.6 million, an increase of $60.3 million from the end of fiscal 2007. The cash and investment balance includes $30.0 million of Auction Rate Securities classified as long- term investments.

GUIDANCE FOR FISCAL 2009

The following statements are based on current expectations. These statements are forward-looking and actual results may differ materially. For a more detailed discussion of forward-looking statements, please see additional information below.

Revenues for 2009 are projected to be in the range of $345.0 million to $355.0 million. Growth in the Cardiovascular
'/>"/>

SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine news :

1. Thoratec Schedules Third Quarter Conference Call, Webcast
2. Thoratecs ITC Division Receives FDA Warning Letter
3. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
4. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
5. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
6. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
8. Thoratec Presentation at Piper Jaffary Conference to be Webcast
9. Thoratec Schedules Fiscal 2008 Year-End Conference Call, Webcast
10. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... CA (PRWEB) September 17, 2014 ... http://www.marijuanastock.net , recently launched a “Video” section ... different cannabis companies in the marijuana industry made ... section, a website visitor is given access to ... relevant to marijuana-related businesses and the issues they ...
(Date:9/17/2014)... 17, 2014 NetDimensions (AIM: NETD; OTCQX: ... management systems, announces the opening of the 2014 Next ... , "We are very excited to meet up in ... interest in Next Steps from our clients and partners, ... really is. We look forward to some very engaging ...
(Date:9/17/2014)... 2014 Tina Griffin, a Senior Sales Associate ... chemotherapy but not her fight against cancer. Though weakened by ... Suncoast “Race for the Cure” on Saturday, Oct. 11, in ... Race for the Cure because I wanted to make an ... As part of her efforts, she is asking those who ...
(Date:9/17/2014)... Angeldress.co.uk is a popular online supplier; ... for worldwide clients. According to Leo, the company’s marketing ... first flagship retail store. Moreover, it is a market ... unveiled its new range of amazing wedding dresses and ... products are offered at greatly discounted prices, from 20% ...
(Date:9/17/2014)... September 17, 2014 In a new ... Dr. William Groff, an expert on the condition known as ... Pearly penile papules , or PPP, is a condition that ... other men may be affected as well. The condition is ... , “While PPP is not a sexually transmitted disease ...
Breaking Medicine News(10 mins):Health News:MarijuanaStock.net Adds Business News Video Section to Their Website 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 2Health News:NetDimensions Next Steps User Conference in North America Opens Today with Record Attendance 3Health News:Tina Griffin’s Fight Against Cancer Didn’t Stop With her Chemotherapy—Her Next Step Is to Run in the Suncoast ‘Race for the Cure’ Oct. 11 2Health News:Angeldress.co.uk Is Planning To Open Its First Retail Store And Offering Big Savings On Amazing Wedding Dresses 2Health News:New Video Depicts Best Treatment for PPP 2Health News:New Video Depicts Best Treatment for PPP 3
... low for people who suffer from traumatic brain injury ... function. TBI can impair a patient,s mental abilities, impact ... And long-term medical treatment carries a high economic cost. ... Air Force, Prof. Chaim Pick of Tel Aviv University,s ...
... , This release is available in German ... Foundation) is to establish 20 Collaborative Research Centres (CRCs) by ... Committee at its spring session in Bonn. The new CRCs ... percent programme allowance for indirect project costs) for the initial ...
... not won in a single battle: Long after a cancer has ... is under debate, and much is unclear. New research led by ... blood cancer, the source of cancer recurrence is in a set ... cells, and thus able to survive chemotherapy. The findings, which appeared ...
... TUESDAY, May 29 (HealthDay News) -- People with less than ... problems with their thinking skills later in life, according to ... researchers from Harvard University noted that people with more education ... thinking, or so-called "cognitive," skills, even if they had the ...
... Dotinga HealthDay Reporter , MONDAY, May 28 (HealthDay ... pounds because her friends sit around? A small study ... after-school programs if they hung out with active kids, and ... that friends directly affect how active kids are, and it,s ...
... treatment for suspected HIV is critical, pre-exposure preventive treatment ... people in high-risk groups, states a review of evidence ... "Although postexposure prophylaxis has a long history of ... treatment in the course of infection ("treatment as prevention") ...
Cached Medicine News:Health News:Diabetes drug could be a promising therapy for traumatic brain injury 2Health News:Diabetes drug could be a promising therapy for traumatic brain injury 3Health News:DFG establishes 20 new Collaborative Research Centres 2Health News:DFG establishes 20 new Collaborative Research Centres 3Health News:DFG establishes 20 new Collaborative Research Centres 4Health News:DFG establishes 20 new Collaborative Research Centres 5Health News:DFG establishes 20 new Collaborative Research Centres 6Health News:Why chemotherapy fails 2Health News:Why chemotherapy fails 3Health News:Education May Protect Brain From Exposure to Solvents 2Health News:Key to More Active, Slimmer Kids: Friends 2Health News:Antiretroviral treatment for preventing HIV infection: an evidence review for physicians 2
(Date:9/17/2014)... MILFORD, Pa. , Sept. 17, 2014  Fortune ... has officially changed its name to Manzo Pharmaceuticals, Inc. ... change to take effect today, September 17, 2014. Also ... split. The approval is a pivotal event ... Manzo . Mr. Manzo explained, "We could not proceed ...
(Date:9/17/2014)... -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a ... an unsolicited, non-binding proposal from Endo International plc (NASDAQ: ... outstanding shares of Auxilium common stock at a price ... subject to due diligence, financing and other conditions. A ... from Endo on Friday evening is reproduced below. ...
(Date:9/17/2014)... -- Mindray (NYSE: MR)announced its new generation DC-70 ultrasound ... been showcased for the first time at ISUOG in ... is scheduled for availability in the U.S. market in ... efficient workhorse in the mid-range segment, the DC-70 combines ... user experience including a gesture-sensitive touch screen, delivering accurate ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7Quality Exams at Your Fingertips 2
... July 29 Micromet, Inc.,(Nasdaq: MITI ), ... treatment of cancer, inflammation and autoimmune,diseases, today announced ... audio,webcast on Thursday, August 7, 2008, at 9:00 ... discuss its second quarter 2008 financial,results. Micromet anticipates ...
... July 28 BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ... study of intravenous (i.v.) peramivir administered via a ... treatment of seasonal,influenza. The trial, conducted by BioCryst,s ... primary endpoint of improvement in the median time ...
Cached Medicine Technology:Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 2Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 2BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 3BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 4BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting 5
... Gemini is the newest addition to Laserscopes ... distinct wavelengths to choose from, 1064nm Nd:YAG ... in an exploding non-invasive aesthetic laser market ... and effectiveness while maintaining the safety and ...
... Surgical Laser System is designed for ... high-power, dual-wavelength system designed for urology, ... surgery, neurosurgery, pulmonary surgery and gastroenterology ... vaporizes and coagulates tissue with minimal ...
... biolitecs Ceralas D 980 nm diode laser ... bloodless field for most surgical procedures. ... cuts optically without collateral tissue damage ... coagulates blood instantly and seals small blood ...
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Medicine Products: